BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor
LYNBROOK, N.Y., Feb. 27, 2013
LYNBROOK, N.Y., Feb. 27, 2013 /PRNewswire/ --BioSpecifics Technologies Corp.
(NASDAQ: BSTC), a biopharmaceutical company developing first in class
collagenase-based products marketed as XIAFLEX^® in the U.S., announced today
that BioSpecifics' President, Tom Wegman, will present at the following
upcoming investor conferences.
oCowen and Company 33rd Annual Health Care Conference (Boston, MA)
Wednesday, March 6, 2013 at 8:40 a.m. EST
oROTH Capital Partners 25th Annual Conference (Laguna Niguel, CA)
Monday, March 18, 2013 at 5:00 p.m. PDT (8:00 p.m. EDT)
The live webcasts of these presentations can be accessed under "Calendar of
Events" in the Investor Relations section of the Company's website at
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for twelve clinical indications. Injectable
collagenase is currently marketed as XIAFLEX^® in the U.S. for the treatment
of adult Dupuytren's contracture patients with a palpable cord by Auxilium
Pharmaceuticals, Inc. (Auxilium) and is approved for Dupuytren's contracture
in the European Union, Switzerland and Canada. XIAFLEX is also in clinical
development for the treatment of several additional promising indications. A
supplemental Biologics License Application is currently under standard review
at the U.S. Food and Drug Administration for XIAFLEX for the potential
treatment of Peyronie's disease. Auxilium is also testing XIAFLEX for frozen
shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase
Ib clinical trials, respectively. BioSpecifics is currently managing the
clinical development of XIAFLEX for the treatment of human lipoma and canine
lipoma, which are both in Phase II clinical trials. Auxilium is currently
partnered with Asahi Kasei Pharma Corporation for the development and
commercialization of injectable collagenase for Dupuytren's contracture and
Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these
same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has
marketing rights to XIAPEX^® (the EU trade name for XIAFLEX) for Dupuytren's
contracture in 46 countries in Eurasia through April 24, 2013. For more
information, please visit www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.
Contact: BioSpecifics Technologies Corp., Thomas L. Wegman, President,
Press spacebar to pause and continue. Press esc to stop.